Document:

Exhibit 10.6

 

 

CONSULTING MARKET ACCESS, 

HEALTH ECONOMICS & OUTCOME 

RESEARCH, FOR IMT (IMPLANTABLE 

TELESCOPE TECHNOLOGY) IN 

EUROPEAN COUNTRIES

 

RESEARCH PREPARED FOR VISIONCARE:

 

NAME : RICHARD P. POWERS 

TITLE : CFO 

	 	TEL : +1 408 329 9123	MOBILE: +1 650 245 2707

EMAIL : POWERS@VISIONCAREINC.NET 

ADDRESS : VISIONCARE, INC. 

 14395 SARATOGA AVE, SUITE 150 

 SARATOGA, CALIFORNIA 95070

 

CODE PROJET : VISIONCARE-CONSULT-2020 

VERSION: 1.0 

DATE: 21/12/2019

 

	 	 	 

 

PREPARED BY :

 

 

Gilles BERDEAUX 

BERDEAUX CONSULTING SAS 

69 Chemin des Alluets 

F-78240 CHAMBOURCY 

Email: gilles.berdeaux@sfr.fr 

Tel: +33.6.17.17.13.50

 

BERDEAUX CONSULTING SAS. RCS VERSAILLES 839 797
875   -   SIRET 839 797 875 00011   -  APE : 7022Z 

TVA Intracommunautaire FR 27 839797875 69 Chemin
des Alluets. F-78240 CHAMBOURCY

 

     

     

    

 

BERDEAUX Consulting SAS (BC) is a company dedicated to market
access activities, both in drugs and medical devices. Our main expertise focused on quantitative evaluation covering various fields: Health
Economics, Patient Reported Outcome, Real World Evidence, Observational Studies, Biostatistics applied to Health Technology Assessment,
among others.

 

As such, BC can support clients strategically to reach their market
access targets (price-volume-time), with or without reimbursement, accounting for an acceptable and expected time to access the market.

 

Dr BERDEAUX is an experienced manager in Health Economics, Outcome
Research and Market Access. Medical Doctor by training, he gained expertise in Biostatistics, Epidemiology and Health Economics, with
a focus on quantitative evaluation. His competencies are about addressing all access, reimbursement, pricing, and technology acquisition
issues by designing and performing the most relevant research studies providing economics and outcomes assessments. He developed research
programs involving both drugs and medical devices in any phases of their life-cycle covering Europe, Middle East and Africa, America and
Asia. He worked both in CROs and industries and have numerous scientific references: 100+ abstracts published, 100+ papers referenced
in Medline, peer reviews in 30+ scientific journals, 10+ scientific society memberships. More than 50% of his scientific works were realized
in the field of eye diseases.

 

Eye diseases have been an important topic of research with two
main area of activities: cataract and age-related macular degeneration (ARMD).

 

BERDEAUX CONSULTING SAS. RCS VERSAILLES 839 797
875   -   SIRET 839 797 875 00011   -  APE : 7022Z 

TVA Intracommunautaire FR 27 839797875 69 Chemin
des Alluets. F-78240 CHAMBOURCY

 

     

     

    

 

On cataract surgery, Dr BERDEAUX
contributed to the evaluation of intra-ocular lenses by several heath technology agencies in European countries with a focus on
posterior capsular opacification (incidence rate, life-long vision and economic consequences) and multifocal implant (benefits
brought to the patients by being free of glasses and economic consequences). He contributed to the development of national
recommendations in France (HAS) and Belgium (KCE) and published 20+ Medline referenced papers on these topics.

 

On age-related macular degeneration, Dr BERDEAUX developed an
epidemiological model to size the targeted population that was used by the Haute Autorité de la Santé when evaluating
Lucentis1. He also documented the burden of ARMD, based on an international pan-European observational survey, to feed health
economics model.

 

Market access successes were reached in numerous area: Market
access/Reimbursement of drugs/devices in Europe/Middle East/Africa/ America/Asia, Drug premium, Reimbursement of devices by private insurance,
DRG funding, Patient co-payment, HTA lobbying, publication of scientific guidelines.

 

Technical skills covered by Dr Berdeaux are the following: Comparative
Effectiveness Research, Observational survey, Prescription database analysis in several countries, Patient reported outcome questionnaire,
Cost and Burden of Illness studies, Cost-effectiveness & Cost-benefit analyses, Budget impact analysis, National Health System
funding analysis, Discrete choice and contingency analysis, Modelling techniques, Biostatistics, Quantitative epidemiology, Data mining,
Decision making analysis support.

 

 

1 Korobelnik JF, Moore N, Blin P, Dharmani C, Berdeaux
G.. Estimating the yearly number of eyes with treatable neovascular age-related macular degeneration using a direct standardization method
and a Markov model. Investigative Ophthalmology and Vision Science 2006 Oct;47(10):4270-6.

 

BERDEAUX CONSULTING SAS. RCS VERSAILLES 839 797
875   -   SIRET 839 797 875 00011   -  APE : 7022Z 

TVA Intracommunautaire FR 27 839797875 69 Chemin
des Alluets. F-78240 CHAMBOURCY

 

     

     

    

 

MISSION

 

BERDEAUX CONSULTING SAS (BC hereunder) has been contacted to advise
VISIONCARE on their European market access activities related to their IMT (Implantable Telescope technology) medical device.

 

IMT is indicated for monocular implantation to improve vision in eyes
of patients at least 65 years of age with severe to profound vision impairment caused by bilateral central scotomas associated with end-stage
age-related macular degeneration (AMD). The magnification with the telescope helps these more peripheral parts of the retina ‘see’
the image and therefore helps patients in their activity of daily living.

 

Today, IMT is reimbursed by Medicare at a price of 20 600US$.
VISIONCARE is seeking reimbursement in some selected European countries, knowing that Medeuronet, a global CRO, has already started investigating
European access of IMT. They suggested the use of Forfait Innovation for France and case by case contracting in Germany and the
NL.

 

BC activities will cover, among other topics:

 

• A review of all scientific works / publications
developed for IMT which took a public health perspective 

• A review of what has been developed by
Medeuronet 

• Gap analysis between existing evidence
and HTA agency expectations 

• Strategy to close the gap aligned with
the business strategy of VISIONCARE: countries of interest, targeted price, acceptance of volume restriction, timing to access the market,
market access budget, market access resources, requested quality and expertise, etc... 

• BC will investigate a broad range of techniques that could be
used to support business objectives of VISIONCARE, such cost effectiveness analysis, real world evidence (based on current sales), utility, medical act coding, health care delivery
organization, national / regional NHS funding analysis, etc...

• When questions will become country specific, BC will seek for
local expertise, endorsed by VISIONCARE.

 

BERDEAUX CONSULTING SAS. RCS VERSAILLES 839 797
875   -   SIRET 839 797 875 00011   -  APE : 7022Z 

TVA Intracommunautaire FR 27 839797875 69 Chemin
des Alluets. F-78240 CHAMBOURCY

 

     

     

    

 

In the case of a gap analysis, BC advises consulting activities to
be performed by block of 50 hours which leaves enough resources for progressing step by step toward a broader market access plan.

 

BUDGET

 

	(C) Vat excl	 	Hourly Cost	 	# Hours	 	Total Cost
	CONSULTING	 	200€	 	50	 	10 000€

 

Consulting calendar will be set-up for each mission between VISIONCARE
and BC and work will be started after VISIONCARE written approval.

 

PAIEMENT

 

An invoice of 5 000€ will be sent to VISIONCARE at the signature
of the contract. Another invoice of 5 000€ will be sent when the 26th consulting hour will be started. Invoices are payable
30 days of the end of the month.

 

BERDEAUX CONSULTING SAS. RCS VERSAILLES 839 797
875   -   SIRET 839 797 875 00011   -  APE : 7022Z 

TVA Intracommunautaire FR 27 839797875 69 Chemin
des Alluets. F-78240 CHAMBOURCY

 

     

     

    

 

BETWEEN :

 

BERDEAUX CONSULTING SAS, 

with registered office at 69, chemin des Alluets, F-78240 Chambourcy 

(hereinafter referred to as “BERDEAUX CONSULTING”)

 

AND:

 

xxxxxx 

(hereinafter referred to as “THE CLIENT”)

 

WHEREAS, THE CLIENT is desirous to have performed certain services
by BERDEAUX CONSULTING with respect to the PROJECT: “CONSULTING HEALTH ECONOMICS – OUTCOME RESEARCH – PATIENT REPORTED
OUTCOME – REAL WORLD EVIDENCE – MARKET ACCESS”

 

WHEREAS, BERDEAUX CONSULTING has the knowledge and the experience to
perform such services;

 

NOW THEREFORE, in consideration of the mutual premises herein contained,
the Parties agree as follows:

 

Article 1: Scope

 

1.1.            BERDEAUX
CONSULTING hereby accepts the assignment under the terms and conditions of present Agreement, to perform on behalf of THE CLIENT the following
services: Market access consulting (hereinafter referred to as “PROJECT”).

 

1.2.            The
PROJECT to be performed by BERDEAUX CONSULTING is described in the following enclosure, which enclosure form an integral part of this
Agreement: CONSULTING HEALTH ECONOMICS – OUTCOME RESEARCH – PATIENT REPORTED OUTCOME – REAL WORLD EVIDENCE – MARKET ACCESS

 

Article 2: Performance of the services

 

2.1.             In
carrying out the PROJECT, BERDEAUX CONSULTING shall make available the resources and personnel, and shall take such steps as it deems
necessary, in order to perform its obligations in accordance with the terms hereof. BERDEAUX CONSULTING shall perform the services in
accordance with the definition and criteria of the PROJECT. BERDEAUX CONSULTING guarantees that it will perform the PROJECT according
to the generally accepted standards of good professional practices; and all applicable laws, rules and regulations relating to the
conduct of the PROJECT. Furthermore, BERDEAUX CONSULTING shall use its best efforts to perform the PROJECT in accordance with the agreed
upon time schedule.

 

2.2.           The
delivered services are provided on an “as is” basis without any further warranties of any kind. BERDEAUX CONSULTING does not
warrant that the delivered services shall meet the present or future needs or objectives of CLIENT and CLIENT assumes sole responsibility
for the use, selection, and suitability of the delivered services to its needs and objectives.

 

2.2.          BERDEAUX
CONSULTING shall develop the PROJECT for THE CLIENT’s consideration and shall not use the data and materials acquired in carrying
out the PROJECT for any purpose other than the PROJECT or disclose it to any person other than THE CLIENT without the express and written
consent of THE CLIENT.

 

2.3.           Should
it appear that the services have not been performed in accordance with the definition and criteria of the PROJECT, or the agreed upon
quality standards, THE CLIENT shall have the right to request BERDEAUX CONSULTING immediately to undertake all modifications, alterations
and additions required to comply with the requirements without any additional cost for THE CLIENT.

 

BERDEAUX CONSULTING SAS. RCS VERSAILLES 839 797
875   -   SIRET 839 797 875 00011   -  APE : 7022Z 

TVA Intracommunautaire FR 27 839797875 69 Chemin
des Alluets. F-78240 CHAMBOURCY

 

     

     

    

 

Article 3: Changes and amendments

 

3.1.            Amendments and substantial changes
to the PROJECT shall be agreed upon by both Parties in writing. All such amendments or changes shall be prepared in writing by BERDEAUX
CONSULTING and communicated to THE CLIENT, stating the consequences on price and terms.

 

3.2.            Either
party retains the right to cancel any and all the work in progress on the PROJECT upon thirty (30) days written notice to the other party.
In case of cancellation of the PROJECT, THE CLIENT agrees to pay for all BERDEAUX CONSULTING’s fees and costs incurred, or contracted
to be incurred, to the date of termination of the PROJECT upon presentation of documentary proof. In the event this Agreement is terminated
by THE CLIENT for any reason except for a breach by BERDEAUX CONSULTING. THE CLIENT shall pay BERDEAUX CONSULTING all reasonable non-cancellable
costs incurred as of the date of termination. For purposes of this Agreement, non-cancellable costs shall mean costs which cannot be prevented
or mitigated, and which arise directly as a result of this Agreement.

 

Article 4: Compensation

 

4.1.           The supply of BERDEAUX CONSULTING
data, information, documentation, analysis, solutions and/or consultancy services shall be subject to BERDEAUX CONSULTING’s acceptance
of the signed Order Form or Proposal or CLIENT’s payment of the invoice.

 

4.2.            If
BERDEAUX CONSULTING has elected to provide Information Services prior to the formal signature of the contract, acceptance of delivery
by CLIENT shall constitute acceptance of the contract without any additional signature of this Agreement being necessary to prove such
acceptance.

 

4.3.          Where
different services are involved, in no event shall CLIENT deduct or off-set any amount(s) against any amount(s) owed to BERDEAUX
CONSULTING’s without BERDEAUX CONSULTING’s prior written consent.

 

4.4.            As
compensation for BERDEAUX CONSULTING’s services, THE CLIENT shall pay to BERDEAUX CONSULTING a fixed fee of maximum 10 000 EUR for
50 hours of consulting (VAT not included), as agreed upon for this PROJECT. Additional costs and expenses that were initially not included
in the PROJECT, shall only be refunded if agreed upon in advance by THE CLIENT in writing.

 

BERDEAUX CONSULTING shall invoice THE CLIENT
in accordance with the following instalments: 

50% at start of the activity 

50% at the 26th consulting hour

 

4.5.            Invoices
are payable within thirty (30) days of the end of the month.

 

4.6.           If
CLIENT fails to pay Fees when due, BERDEAUX CONSULTING may charge in addition to the invoiced amount, interest at a rate equal to the
discount rate charged by the central bank of the billing currency plus 5% (five percent) per annum on the unpaid balance beginning thirty-five
(35) days from the date of the invoice until such amounts are paid.

 

Article 5: Audit

 

During the term of this Agreement, BERDEAUX CONSULTING’s facilities,
may during reasonable business hours be inspected by THE CLIENT or by a person appointed by THE CLIENT, with the right to inspect and
to have access to such records separately kept by BERDEAUX CONSULTING, in order to verify the compliance with the agreed upon quality
standards.

 

BERDEAUX CONSULTING SAS. RCS VERSAILLES 839 797
875   -   SIRET 839 797 875 00011   -  APE : 7022Z 

TVA Intracommunautaire FR 27 839797875 69 Chemin
des Alluets. F-78240 CHAMBOURCY

 

     

     

    

 

Article 6: Documents and Materials

 

6.1.           THE
CLIENT shall provide BERDEAUX CONSULTING in due time with all the documentation, information and instructions relating to the PROJECT
and necessary to enable BERDEAUX CONSULTING to perform the services under this Agreement. All such information shall remain the property
of THE CLIENT at all times, irrespective of whether this information has been made available by THE CLIENT or has been produced by BERDEAUX
CONSULTING as part of the PROJECT.

 

6.2.           BERDEAUX
CONSULTING agrees to provide, at its own cost and expense all labour necessary for the performance of the PROJECT, unless otherwise agreed
upon. All equipment and machinery supplied by THE CLIENT, shall remain the property of THE CLIENT at all times.

 

Article 7: Intellectual property rights

 

All transmittable intellectual property rights directly resulting from
the performance of the services and any other titles to publish, copy or commercialize them worldwide shall be transmitted by BERDEAUX
CONSULTING to THE CLIENT and THE CLIENT shall be free to use and exploit such results at its discretion. BERDEAUX CONSULTING will not
be responsible for the use and exploitation of the PROJECT and its results by THE CLIENT.

 

Article 8: Confidentiality

 

8.1.             BERDEAUX
CONSULTING acknowledges that all information divulged or communicated or in any other way disclosed to him under the present Agreement
is strictly confidential. The disclosure will therefore be subject to the following obligation of confidentiality and non-use.

 

8.2.            BERDEAUX
CONSULTING shall maintain in confidence all such information received from THE CLIENT. BERDEAUX CONSULTING shall not disclose such confidential
information to any third party nor use such information for any purpose other than performing the above-mentioned services to THE CLIENT.
Upon THE CLIENT’s first request, BERDEAUX CONSULTING shall immediately return to THE CLIENT all physical embodiment of such confidential
information (if any).

 

8.3.             The
obligation of confidentiality and non-use of this Article shall not apply to information that: 

a) was known in the public domain or subsequently
enters into the public domain through no fault of BERDEAUX CONSULTING; 

b) BERDEAUX CONSULTING receives from a third
party not under obligation to keep such information confidential: 

c) is required to be disclosed by law; 

d) was disclosed subject to THE CLIENT’s prior written consent.

 

8.4.             The
above obligations shall survive the termination of this Agreement for a period of ten (10) years.

 

Article 9: Term

 

Unless sooner terminated as hereinafter provided, this Agreement shall
enter into force and effect on START DATE and shall continue in full force and effect until the above mentioned services have been completed,
which completion shall in no event be later than END DATE.

 

Article 10: Termination

 

10.1.          If
BERDEAUX CONSULTING shall commit any breach of any covenant or agreement herein detained, and shall fail to remedy such breach within
thirty (30) days after receipt of written notice thereof by THE CLIENT, or should ownership of or control over BERDEAUX CONSULTING be
transferred to others than those presently holding ownership of or control over BERDEAUX CONSULTING, notice of which transfer shall be
promptly given to THE CLIENT, or if BERDEAUX CONSULTING becomes insolvent. THE CLIENT may, at its option and by written notice, terminate
this Agreement and the rights herein granted immediately without any prior notice.

 

BERDEAUX CONSULTING SAS. RCS VERSAILLES 839 797
875   -   SIRET 839 797 875 00011   -  APE : 7022Z 

TVA Intracommunautaire FR 27 839797875 69 Chemin
des Alluets. F-78240 CHAMBOURCY

 

     

     

    

 

10.2.            Furthermore,
THE CLIENT may, at its option and by written notice, terminate this Agreement should BERDEAUX CONSULTING’s premises and/or records
not comply with the agreed upon quality standards, THE CLIENT shall have the right to terminate this Agreement, without incurring any
liability, provided that BERDEAUX CONSULTING would have failed to start the necessary corrective action within thirty (30) days after
having been notified of such situation.

 

10.3.            Irrespective
the way in which the Agreement is terminated, BERDEAUX CONSULTING shall immediately return to THE CLIENT the results of its assignment
hereunder, together with all data, information and materials received from THE CLIENT.

 

Article 11: Indemnification

 

11.1.            THE
CLIENT hereby waives and agrees to indemnify, defend and hold BERDEAUX CONSULTING harmless from and against any loss, claim, damage or
liability of any kind occasioned by THE CLIENT or its employees or its or their use of materials arising out of or in connection with
this Agreement.

 

11.2.            BERDEAUX
CONSULTING shall hold THE CLIENT harmless for any loss, claim, damage or liability of any kind to the extent caused by the negligence,
recklessness or wilful misconduct of BERDEAUX CONSULTING or its employees in performing the services under this Agreement, but BERDEAUX
CONSULTING will not be liable for any special, incidental or consequential damages including but not limited to loss of revenue or profit
in connection with or arising out of performance of this Agreement. BERDEAUX CONSULTING will secure and maintain in full force and effect
throughout the term of this Agreement insurance coverage of General Liability in amounts appropriate to the conduct of BERDEAUX CONSULTING’s
business. Upon request, BERDEAUX CONSULTING shall furnish THE CLIENT with certificates evidencing the required insurance coverage.

 

Article 12: Relationship of the Parties

 

BERDEAUX CONSULTING, for all purposes related to this Agreement, shall
be deemed an independent contractor of THE CLIENT, and nothing in this Agreement shall be deemed to create a relationship of employment
or agency or to constitute the Parties as partners or joint ventures.

 

Article 13: Use of Names

 

Save as required by law no announcement or circular in connection with
the subject matter of this Agreement shall be made by or on behalf of BERDEAUX CONSULTING or THE CLIENT without the prior approval of
the other Party, such approval not to be unreasonably withheld or delayed.

 

Article 14: Force majeure

 

14.1.            Except
as otherwise herein provided, neither Party shall be liable or deemed in default for failure to perform any duty or obligation that such
Party may have under this Agreement where such failure has been occasioned by any act of God, fire, strike, inevitable accidents, war,
or any other cause outside the reasonable control of that Party and occurring without its fault or negligence.

 

14.2.          The
Party whose performance has so been interrupted shall give the other Party notice of the interruption and cause thereof and shall use
every reasonable means to resume full performance of this Agreement as soon as possible.

 

Article 15: Assignment and Subcontracting

 

Neither this Agreement nor the rights or obligations hereunder shall
be assignable or otherwise transferred or subcontracted by BERDEAUX CONSULTING or THE CLIENT without prior written approval of the other
party, except to respective Affiliates.

 

BERDEAUX CONSULTING SAS. RCS VERSAILLES 839 797
875   -   SIRET 839 797 875 00011   -  APE : 7022Z 

TVA Intracommunautaire FR 27 839797875 69 Chemin
des Alluets. F-78240 CHAMBOURCY

 

     

     

    

 

Article 16: Notices

 

Any notice required under this Agreement shall be made in writing by
registered mail or facsimile to the Parties, at their respective addresses first above written or as subsequently changed by notice. Notice
sent by mail shall be effective three (3) days after posting; notice sent by facsimile shall be effective when sent.

 

Article 17: Modification of Contract

 

No waiver or modification of this Agreement or of any covenant, condition
or limitation herein contained shall be valid and no evidence of waiver or modification shall be offered or received in evidence of any
proceeding or litigation between the Parties hereto arising out of or affecting this Agreement or the rights or obligations of the Parties
hereunder, unless such waiver or modification is in writing, duly signed by both Parties.

 

Article 18: Applicable law and jurisdiction

 

The present Agreement is governed by French law. In the event of disputes
relating to the interpretation or performance of the present Agreement, the parties shall attempt to reach an amicable settlement. If
such an amicable settlement should fail, the dispute shall be submitted exclusively to the courts of Nanterre, France.

 

BERDEAUX CONSULTING SAS. RCS VERSAILLES 839 797
875   -   SIRET 839 797 875 00011   -  APE : 7022Z 

TVA Intracommunautaire FR 27 839797875 69 Chemin
des Alluets. F-78240 CHAMBOURCY

 

     

     

    

 

	CLIENT	 	BERDEAUX CONSULTING SAS
	 	 	 
	Date	 	Date 21/12/2019
	 	 	 
	Signature	 	Signature
	 	 	 
	/s/ Richard Powers	 	/s/ Gilles Berdeaux
	 	 	 
	Name Richard POWERS	 	Name Gilles BERDEAUX
	 	 	 
	Title EVP & CFO	 	Title Président
	 	 	 
	Company VISION CARE INC.	 	 
	 	 	 
	Address 14395 SARATOGA AVE	 	Address
	 	 	 
	 	 SUITE 150	 	69 Chemin des Alluets
	 	 	 
	 	 SARATOGA 95070	 	F-78240 CHAMBOURCY

 

BERDEAUX CONSULTING SAS. RCS VERSAILLES 839 797
875   -   SIRET 839 797 875 00011   -  APE : 7022Z 

TVA Intracommunautaire FR 27 839797875 69 Chemin
des Alluets. F-78240 CHAMBOURCYExhibit 10.8

 

FINANCIAL ADVISORY AGREEMENT

Addendum

 

This Agreement is entered into as of January 13,
2020 (the “Effective Date”) by and between VisionCare Inc., a Delaware company having an address at 14395 Saratoga
Ave, Suite 150 Saratoga, California, U.S.A. (the “Company”) and Mr. Steve Cohen, an individual with U.S.A.
passport and its partner, Gold Coast Advisory Ltd. having an address at Together as the “Banker”). The Banker and the
Company each a “Party” and collectively the “Parties”.

 

WHEREAS, the Company is engaged in the research,
development, manufacturing and commercialization of implantable ophthalmologic telescope for near-blind patients and is interested to
consummate Qualified Transactions (as defined below) with the Company and/or its shareholders and/or any of the Company’s affiliates
and subsidiaries; and

 

WHEREAS, the Banker has extensive experience
in identifying strategically potential business partners (the “Prospects”) and support the Company leading to the signature
of a Qualified Transaction; and

 

WHEREAS, the Parties desire to collaborate,
under the terms and conditions set forth hereunder.

 

NOW THEREFORE, in consideration of the premises
and the mutual promises set forth in this Agreement, and in consideration of the representations, warranties and covenants contained herein,
the Parties, intending to be legally bound hereby, agree as follows:

 

1.             The
Services

 

1.1.          The
Banker hereby agrees to provide the Company with the Services for the Term of this Agreement, as defined in Section 4.1 herein,
and the Company hereby agrees to receive the Services from the Banker during the Term, all subject to the terms and conditions set forth
herein.

 

1.2.          As
part of the Servicer, the Banker will use commercially reasonable best efforts to identify and introduce Prospects to the Company that
will be interested in entering a Qualified Transaction(s) (as defined herein) with the Company and/or any of its affiliates and subsidiaries.
In connection with the provision of the Services, the Bank will also use commercially reasonable best efforts to:

 

		(a)	To the extent appropriate and feasible, familiarize itself with the business, properties and operations of the Company;

 

		(b)	Assist in the preparation of confidential marketing materials (including a customary confidential information memorandum) regarding
the Company for presentation to Prospects, which shall be reviewed for accuracy and completeness, and approved, by the Company;

 

		(c)	Assist the Company with coordinating the presentation of data room materials in connection with a Qualified Transaction for Prospects
(it being understood that the costs and expenses of any such data room shall be borne entirely by the Company);

 

     

    - 2 -

    

 

		(e)	Assist in approaching, soliciting and evaluating proposals from Prospects, structuring a Qualified Transaction and negotiating a definitive
agreement for the Transaction.

 

1.3.          Prospects
which expressed interest in a Qualified Transaction and who are approved by the Company (each, an “Approved Prospect”)
shall be listed in Exhibit “A”. Banker will update the list of Approved Prospects in Exhibit “A”
as needed.

 

1.4.          Prospects
originating from the network of the Company (each, an “Excluded Prospect”) are listed in Exhibit “C”.
Those Prospects are excluded from this Agreement. The Company will promptly update the list of Excluded Prospects in Exhibit “C”.

 

1.5.          All
new Prospects, including Prospects that directly approach the Company after the date hereof, but prior to termination, without the Banker’s
intermediation, shall be deemed Excluded Prospects unless they are mentioned in or added to and approved by the Company in the list in
Exhibit “A” of Approved Prospects.

 

1.6.          Any
direct Affiliate of an Approved Prospect shall also be considered an Approved Prospect. The term “Affiliate” herein
shall mean any entity, which, directly or indirectly, owns, is owned by or under common ownership with or controls, or is controlled by
the applicable entity, whereby the terms “control” and “own” shall mean the power to direct the affairs of the
relevant entity or the ownership of more than 50% of the voting securities of such entity through equity interest, contract or otherwise.

 

1.7.          Notwithstanding
the Services provided by the Banker, the Company shall have the sole and complete discretion to enter into or refrain from entering into
any agreement with any Approved Prospect and will retain complete and final control of all key decisions in connection with a Qualified
Transaction, including, without limitation, those decisions concerning: (a) strategy and pricing; (b) the structure and form;
(c) the descriptive memorandum and other information presented to Prospects; (d) Prospects permitted to receive the descriptive
memorandum; (e) Prospects allowed to conduct due diligence and to be included in the final sales process; (f) the selection
of the preferred Prospect; (g) the acceptance of a letter of intent or agreement in principle; and (h) the entry into a definitive
agreement.

 

1.8.          The
Company shall notify the Banker of any offers received for a Qualified Transaction with sufficient time for the Approved Prospects of
the Banker to make a more attractive offer to the Company.

 

2.             Compensation

 

2.1.          The
Company shall pay the Banker a fee in the amount and under the terms as set forth in Exhibit “B” attached
hereto (“Banker Fee”).

 

2.2.          Following
each payment made by the Company to the Banker, the Banker shall issue the Company an invoice. The Company will issue 1099 MISC statements
corresponding to these invoices.

 

2.3.          The
Banker Fee to be paid to the Banker pursuant to the terms and conditions of this Agreement constitute the full and complete consideration
due to the Banker in respect to the fulfillment of his undertakings herein, unless otherwise agreed upon by the Parties.

 

     

    - 3 -

    

 

3.             Information

 

3.1.          The
Company recognizes and confirms that the Banker (i) will use and rely solely on the information supplied by the Company and its representatives
and on information available from generally recognized public sources (collectively, the “Information”) in performing
the Services contemplated by this Agreement without having assumed any obligation to verify or investigate independently the same; (ii) does
not assume responsibility for the accuracy or completeness of the Information and such other information; and (iii) has not been
asked to and will not conduct a physical inspection of any properties or assets of the Company or any other party or make or obtain any
independent evaluation or appraisal of any assets or liabilities (contingent or otherwise) of the Company or any other party.

 

3.2.          Absent
gross negligence, willful misconduct or fraud, the Banker shall have no liability whatsoever in connection with any Prospect and the Company
shall not make any claim or hold the Banker liable for any damages, expenses or liabilities, including without limitation, loss of profits,
injury to business reputation or other damages of any kind resulting from the continuation or abandonment of any negotiations or transaction
with any Prospect.

 

3.3.          The
Company holds the Banker harmless from any claim made by Approved Prospects arising from Qualified Transactions.

 

4.             Term

 

4.1.          Except
as provided for herein, the term of this Agreement shall be for a period of twelve (12) months commencing as of the Effective Date (the
 “Term”). The foregoing notwithstanding, either Party may terminate this engagement at any time, with or without cause,
upon written notice to the other Party; provided that the Company shall not be under any obligation to reimburse the Banker for
any fees or expenses incurred following the date of such notice of termination. In the event of any such termination by the Company, the
Banker will use commercially reasonable efforts to cooperate with the Company to effect an orderly transition to another financial advisor
(if applicable).

 

4.2.          In
any case of expiration or termination of this Agreement, the Company may continue negotiations and/or any other activity with any Approved
Prospect, subject to the Banker’s rights as provided herein, including his right to receive the Banker’s Fee.

 

4.3.          The
Company shall update the Banker, notwithstanding the termination or expiration of this Agreement, on any progress made with Approved Prospects
and deliver to it, upon Banker’s first request, a written report with respect thereto.

 

4.4.          In
addition, except as provided herein, the Banker shall be entitled to the full amount of the Banker Fee in the event a Qualified Transaction
(but excluding any letter of intent, term sheet or other similar preliminary document) is consummated with any Approved Prospect at any
time within one (1) year from the date of termination.

 

4.5.          The
foregoing notwithstanding, if (x) this Agreement is terminated by the Company due to the gross negligence, willful misconduct or
bad faith of the Banker, or (y) during the 90 days period following the Effective Date, the Banker terminates this Agreement for
any reason, other than as a result of a breach by the Company of which the Company received written notice and the Company failed to cure
such breach within 30 days following such receipt, then the Banker shall not be entitled to receive a Banker Fee or any other compensation
or remuneration pursuant to the terms of this Agreement

 

4.6.          Notwithstanding
any such expiration or termination, the provisions in Section 5 of this letter agreement shall survive and remain in full
force and effect and be binding on the parties and their respective successors and assigns.

 

     

    - 4 -

    

 

5.             Miscellaneous

 

5.1.          Additional
Fees. Without the prior approval of the Company the Banker shall not, directly or indirectly, receive any additional fees and/or other
payments from the Prospects in connection with any Qualified Transaction contemplated under this Agreement.

 

5.2.          Entire
Agreement. This Agreement together with the preamble and the Exhibits hereto contains the entire agreement between the Parties with
respect to the subject matter hereof, and supersedes all prior agreements, arrangements and understandings, written or oral, relating
to the subject matter hereof, if any.

 

5.3.          Parties’
Relationship. It is expressly acknowledged and agreed that in rendering the Services hereunder, the Banker shall act solely as an
independent contractor and neither this agreement nor the performance hereof shall be construed as creating between the Company and the
Banker, any partnership, joint venture, employment relationship, franchise or agency or any other similar relationship.

 

5.4.          Governing
Law; Jurisdiction. The validity, performance and construction of this Agreement shall be governed by and interpreted exclusively in
accordance with the laws of the State of New York, without giving regard to the rules of conflict of law. The Company and the Banker
hereby (a) irrevocably consent to personal jurisdiction in the Supreme Court of the State of New York in New York County, Commercial
Part, or any Federal court sitting in the Southern District of New York, for the purposes of any suit, action or other proceeding arising
out of this letter agreement or any of the agreements or transactions referred to herein or contemplated hereby, which is brought by or
against the Company or the Banker, as applicable, (b) waive any objection to venue with respect thereto, and (c) agree that
all claims in respect of any such suit, action or proceeding may be heard and determined in any such court, and that such courts shall
have jurisdiction over any claims arising out of or relating to the letter agreement or such agreements or transactions, and agree not
to commence any suit, action or proceeding arising out of or relating to the Agreement except in such courts. The Company or the Banker,
as applicable, hereby irrevocably consents to the service of process of any of the aforementioned courts in any such suit, action or proceeding
by the mailing of copies thereof by registered or certified mail, postage prepaid, to the Company or the Banker, as applicable, such service
to become effective ten (10) days after such mailing. Any right to trial by jury with respect to any claim or action arising out
of this letter agreement or conduct in connection with this engagement is hereby waived.

 

5.5.          Amendments.
Any alteration, amendment or modification of, addition to or deletion from this Agreement or any of its provisions shall have no effect
unless made in writing and signed by the Parties to this Agreement.

 

5.6.          Failure.
The failure of a Party at any time or times to require performance of any provision hereof shall in no manner affect the right of such
Party at a later time to enforce the same. No waiver by a Party of the breach of any term or covenant contained in this Agreement, whether
by conduct or otherwise, in any one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of any breach,
or waiver of the breach of any term or covenant contained herein.

 

5.7.          Notices.
All notices given by one Party to the other hereunder shall be as per the addresses indicated in the preamble above, or such other address
as a party may thereafter give notice in accordance herewith, and shall be in writing and will be deemed to have been delivered to the
addressee: on the next business day following the day of delivery or transmission, or within three (3)days after being posted, if sent
by registered mail, postage prepaid.

 

     

    - 5 -

    

 

5.8.          Confidentiality.
The Banker agrees that all nonpublic information furnished by or on behalf of the Company to the Banker in connection with this engagement,
whether prior to or after the date hereof, as well as the nature and substance of any discussion between the Banker, the Company and any
Prospects concerning a Qualified Transaction, shall be treated as confidential information and shall not be disclosed to any third party
(except as required by law, rule or regulation, and then only on prior notice to the Company so that the Company may take such actions
as a reasonable necessary, at its own cost and expense, to protect such disclosure).

 

5.9.          Counterparts.
This letter agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute
one and the same instrument. Transmission by telecopy, facsimile, email or other form of electronic transmission of an executed counterpart
of this letter agreement shall be deemed to constitute due and sufficient delivery of such counterpart.

 

5.10.        Addendum

 

The addendum dated January 13, 2020 extends the termination
date to December 31, 2020 of the consultant agreement between VisionCare Inc. and Mr. Steve Cohen dated November 8, 2018.

 

[Signature page follows]

 

     

    - 6 -

    

 

IN WITNESS WHEREOF, the Parties hereto have
caused this Agreement to be duly executed, in one or more counterparts, on the day and year first set out above:

 

	VisionCare Inc.	Steve Cohen	Gold Coast Ltd.
	 	 	 
	By:	 Richard Powers	 	By:
	Title:	EVP & CFO,	 	Title:
	 	VisionCare&Inc.	 	 
	 	 	 
	/s/ Richard Powers	 	 
	1-13-20	 	 

 

     

    - 7 -

    

 

Exhibit “B”

 

Compensation

 

The Banker will be entitled to the following fees:

 

1.             Definitions.
For purposes of this Agreement, the following terms shall have the meanings set forth opposite them:

 

“Consideration” shall mean the
total valuation of the Qualified Transaction, which: (a) in the case of a sale, exchange or purchase of the Company’s equity
securities, the total consideration paid for such securities or (b) in the case of a sale or disposition of the Company’s assets,
the total consideration paid for such assets less all liabilities of the Company related to the assets sold or disposed
of. Amounts paid into escrow and contingent payments in connection with any Qualified Transaction will be included as part of the Consideration.
Amounts paid into escrow will be included as part of Consideration and payable upon the establishment of such escrow. If the Consideration
in connection with any Qualified Transaction may be increased by payments related to future events, the portion of the Success Fee relating
to such contingent payments will be calculated and paid if and when such contingent payments are actually made. If any portion of the
aggregate consideration is paid in the form of securities, the value of such securities, for purposes of calculating the Success Fee,
will be determined by the average of the last sales prices for such securities on the five trading days ending five trading days prior
to the date of the consummation of the Qualified Transaction (as reported in the Wall Street Journal). Warrants and options shall
be valued using the treasury stock method without giving effect to tax implications. If such securities do not have an existing public
trading market, the value of the securities shall be the mutually agreed upon fair market value on the day prior to the consummation of
the transaction.

 

“Qualifying Period” shall mean
the Term and a period of ‘12’ months thereafter.

 

“Qualified Transaction” shall
mean a transaction involving the sale of all of the Company’s outstanding equity securities or a sale of all or substantially all
of the Company’s assets (taken as a whole). Distribution agreements involving the selling or transferring of certain rights for
distribution of any of VisionCare’s product are not considered a qualified transaction and are not part of the Consideration. A
different fee structure as per below applies.

 

“Term Sheet” shall mean the nonbinding
agreement between the Company and one Approved Prospect setting forth the basic terms and conditions under which the Qualified Transaction
will be made.

 

Success Fee.

 

a)             Success
Fee for a sale of the company: Five percent (5%) of the Consideration.

 

The Success Fee shall be payable within one week of reception
of the first tranche of funds received out of the Consideration (except as provided in the definition thereof).

 

     

    - 8 -

    

 

Success fee for a successful distribution agreement: A success
fee of $100,000 plus a royalty on any net payments to VisionCare from the distributor for goods sold to the distributor in the amount
of 3% but with a maximum payout to Banker capped at $1 Million. Such royalty payments will be made to Banker after payments from distributor
are received and on a quarterly basis.

 

		(a)	Late Fee. Any amounts payable pursuant to this Agreement and not paid within 30 days of their due date will incur interest
at the rate of 1.5% (one point five percent) per month. Notwithstanding the foregoing, this paragraph shall not be interpreted as granting
a right to defer payment of any amounts due under this Agreement.

 

		(b)	Expenses. Banker will be reimbursed by the Company for all reasonable and documented and approved out-of-pocket expenses plus
Value Added Tax (VAT) (if any) directly related to the Services. Such expenses may include, but are not limited to, travel and accommodation
expenses. Banker will seek in advance written approval (which may include via e-mail) from the Company for any expenses incurred.

 

		(c)	Taxes. The Success Fee does not include Value Added Tax or Withholding Taxes which shall be added, if applicable, against issuance
of tax invoice with respect to each payment.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}]]